Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma ...

Phase III progression-free survival data were positive for first-line Braftovi in first-line combination therapy for mCRC.

EyePoint has entered the final phase of development for its lead product, Duravyu, announcing the completion of patient ...

Alvotech and UK-based Advanz Pharma sign agreement to commercialise three additional biosimilar candidates in Europe.

A new NDA was submitted in January 2024, which the FDA did accept, and that was later converted into a priority review. An ...

Astellas Pharma has signed an exclusive licensing agreement with Evopoint Biosciences for XNW27011, a CLDN18.2-targeting ...

Daiichi and MSD have voluntarily withdrawn the BLA in the US for their patritumab deruxtecan for treating non-small cell lung ...

The HSS has terminated a contract previously awarded to Moderna to help advance a vaccine candidate targeting bird flu.

Merck KGaA is filing for global regulatory approvals of pimicotinib after it met primary and secondary endpoints in a Phase ...

Drug pricing and reimbursement constraints are a major concern for the pharmaceutical industry. In order to balance ...

Expanding the reach of CAR-T therapeutics could unlock promising new treatment possibilities for solid tumour patients.

Telesis Bio has announced a licensing agreement with Regeneron, enabling the latter to deploy the Gibson SOLA platform at R&D ...